Reckitt Benckiser Group Plc (LON:RB) has received a consensus rating of “Hold” from the twenty research firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, six have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is GBX 6,986.88 ($91.30).
Several research firms have recently weighed in on RB. Deutsche Bank reissued a “buy” rating and set a GBX 8,000 ($104.53) price objective on shares of Reckitt Benckiser Group in a research note on Wednesday. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 9,000 ($117.60) price objective on shares of Reckitt Benckiser Group in a research note on Monday, April 15th. Barclays reissued an “overweight” rating and set a GBX 7,500 ($98.00) price objective on shares of Reckitt Benckiser Group in a research note on Monday, April 15th. Jefferies Financial Group set a GBX 5,400 ($70.56) price objective on Reckitt Benckiser Group and gave the stock a “sell” rating in a research note on Thursday, April 11th. Finally, UBS Group reissued a “neutral” rating and set a GBX 6,400 ($83.63) price objective on shares of Reckitt Benckiser Group in a research note on Wednesday, April 10th.
In other news, insider Andrew R. J. Bonfield acquired 80 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The stock was acquired at an average cost of GBX 5,760 ($75.26) per share, for a total transaction of £4,608 ($6,021.17). Also, insider Elane Stock acquired 1,860 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The shares were purchased at an average price of GBX 6,233 ($81.45) per share, with a total value of £115,933.80 ($151,488.04).
Shares of RB traded up GBX 44.20 ($0.58) during trading hours on Tuesday, hitting GBX 5,812 ($75.94). 1,894,743 shares of the company were exchanged, compared to its average volume of 1,720,000. The firm has a market cap of $41.14 billion and a PE ratio of 19.07. The company has a quick ratio of 0.47, a current ratio of 0.65 and a debt-to-equity ratio of 80.49. Reckitt Benckiser Group has a one year low of GBX 5,255 ($68.67) and a one year high of GBX 7,174 ($93.74).
The firm also recently announced a dividend, which will be paid on Thursday, May 23rd. Stockholders of record on Thursday, April 18th will be issued a GBX 100.20 ($1.31) dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a dividend yield of 1.67%. This is a positive change from Reckitt Benckiser Group’s previous dividend of $70.50. Reckitt Benckiser Group’s dividend payout ratio is presently 0.66%.
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: Are sell-side analysts objective?
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.